Introduction
============

Multiple sclerosis (MS) is a chronic inflammatory disease affecting the central nervous system (CNS) in adults. It leads to myelin loss, varying degrees of axonal pathology, and progressive disability ([@b1-mmr-14-04-3543]). The causes of MS remain largely unknown; however, genetic and environmental components are involved in susceptibility and disease outcome, however their relative roles are poorly understood ([@b2-mmr-14-04-3543]).

No cure currently exists, however, the variety of available treatments is broadening, particularly for the relapsing-remitting form of MS (RRMS) ([@b3-mmr-14-04-3543],[@b4-mmr-14-04-3543]). The use of different formulations of interferon-β (IFN-β) and glatiramer acetate has reduced the relapse rate and the development of new lesions (as detected by magnetic resonance imaging) ([@b5-mmr-14-04-3543]). More therapeutic agents to treat MS, and the development of biomarkers to predict treatment response are required ([@b6-mmr-14-04-3543]). Genome-wide association studies (GWAS) have notably contributed to the understanding of MS susceptibility. The final aim of GWAS is to use genetic risk factors to make predictions regarding susceptibility to the disease, identify the underlying molecular mechanism and, thus, facilitate the development of novel prevention and therapeutic strategies.

A total of 23 non-human leukocyte antigen (HLA) loci associated with MS were identified by 7 independent GWAS and 1 meta-analysis conducted between 2007 and 2011 ([@b7-mmr-14-04-3543]--[@b11-mmr-14-04-3543]). 10 GWAS have been performed in MS subjects. There were follow-up studies that resulted in the identification of 16 confirmed loci with genome-wide significance. Numerous risk variants are located at or near genes with central immunological functions. The majority are associated with other autoimmune diseases ([@b12-mmr-14-04-3543]). The Wellcome Trust Case Control Consortium 2 in collaboration with the International MS Genetics Consortium has recently completed the largest MS GWAS to date and increased the number of non-HLA genetic loci associated with MS to 57 loci ([@b13-mmr-14-04-3543]). However, additional genetic and functional studies are required to identify the function of these relevant genes and pathways. In 2009, Comabella *et al* ([@b14-mmr-14-04-3543]) published a whole-genome study investigating single nucleotide polymorphisms (SNPs) associated with IFN-β therapy response. Top-scoring intragenic SNPs are localized in the following genes: Zinc finger and AT hook domain containing (*ZFAT*), glutamate receptor, ionotropic, AMPA 3 (*GRIA3*), StAR-related lipid transfer (START) domain containing 13 (*STARD13*), adenosine deaminase, RNA-specific (*ADAR*), zinc finger homeobox 4 (*ZFHX4*), interferon (α, β and ω) receptor 2 (*IFNAR2*) and citron Rho-interacting serine/threonine kinase (*CIT*). The *GRIA3* gene encodes an AMPA-type glutamate receptor.

It has been reported that glutamate is important in the CNS ([@b15-mmr-14-04-3543]) and the majority of the excitatory synaptic transmission in the CNS is mediated by AMPA-type glutamate receptors expressed in oligodendrocytes ([@b16-mmr-14-04-3543]). Oligodendrocytes are highly susceptible to excitotoxic signals mediated by AMPA receptors, this indicates that oligodendrocyte excitotoxicity may be implicated in the pathogenesis of demyelinating disorders, including MS ([@b17-mmr-14-04-3543]). CIT is found on postsynaptic sites of glutamatergic and GABAergic neurons interacting with a scaffold protein, postsynaptic density protein 95 ([@b18-mmr-14-04-3543]), predicting potential cross-talk between these two signaling pathways. This is important in numerous aspects of neural plasticity.

In 2005, Leyva *et al* ([@b19-mmr-14-04-3543]) proposed a role for the IFNAR pathway in susceptibility to MS. ADAR is an IFN-inducible RNA-specific adenosine deaminase implicated in the editing of viral RNA transcripts and cellular pre-mRNAs. Liu and Samuel ([@b20-mmr-14-04-3543]) associated increases in ADAR levels to glutamate receptor function. ZFAT and ZFHX4 genes encode for zinc finger proteins, while STARD13 encodes for a GTPase-activating enzyme. In addition, their possible association with response to IFN-β or MS susceptibility remains unknown.

However, none of these genes are currently confirmed as MS risk genes. Genetic associations with MS are less studied in individuals from the Arabian Peninsula. To date, Al Jumah *et al* ([@b21-mmr-14-04-3543]) has reported the only genetic study confirming a subset of SNPs identified by GWAS as MS-associated in Saudi MS patients. This suggests that further studies of MS genetic susceptibility in the Arabian Peninsula population are required.

The Arab Gulf population has a lower risk of MS compared to Europeans and white Americans. However, recent studies demonstrated an increase in incidence and prevalence of MS, particularly among women within the Arab Gulf region (31--55 MS cases/100,000 individuals) ([@b22-mmr-14-04-3543],[@b23-mmr-14-04-3543]). Considering the geographic nature of environmental and genetic factors contributing to the development of MS, the present study investigated the potential role of polymorphisms in the genes encoding ZFAT, GRIA3, STARD13, ADAR, ZFHX4, IFNAR2 and CIT on MS susceptibility.

Materials and methods
=====================

Sample collection
-----------------

A group of unrelated Arab patients with RRMS were recruited for the current study from different centers in the Arabian Gulf \[156 subjects (88 women and 68 men)\]. MS patients were clinically diagnosed with MS according to McDonald\'s criteria ([@b24-mmr-14-04-3543]). Disease severity was measured using the Expanded Disability Status Score (EDSS) ([@b25-mmr-14-04-3543]); 96 out of 156 MS patients were treated with IFN-β. However, the remaining 60 patients received other treatments, including Gilenya, Tysabri (natalizumab), carbamazepine or steroids (cortisone). Patients were considered responders to IFN-β when there were no relapses with any increase in the EDSS score during the follow-up period (2 years). Non-responders were those who experienced ≥1 relapses with an increment of at least one point in the EDSS score during the two years of treatment ([@b26-mmr-14-04-3543]). A total of 68 patients were considered responders and 17 as non-responders to IFN-β treatment, in addition 11 MS patients did not have complete records for EDSS and relapse scores. The control group included 112 healthy individuals, 64 women and 48 men, from the same region with no personal or familial (first-degree relatives) history of autoimmune diseases. All participants provided written informed consent and the present study was approved by the ethics committee of the Arabian Gulf University (Manama, Bahrain).

SNP selection and genotyping
----------------------------

Seven SNPs were previously reported to be associated with response to INF-β treatment: rs12557782 in *GRIA3*, rs7308076 in *CIT*, rs2229857 in *ADAR*, rs733254 in *ZFAT*, rs9527281 in *STARD13*, rs11787532 in *ZFHX4*, and rs2248202 in *IFNAR2*) ([@b14-mmr-14-04-3543]). Genomic DNA was isolated from blood samples using the Blood & Cell Culture DNA Mini kit, and EZ1 DNA Investigator Kit (Qiagen, Inc., Valencia, CA, USA) according to the manufacturer\'s protocols. SNP genotyping was performed by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) and KBioscience Competitive Allele-Specific PCR genotyping technique (KASP) methods. The present study genotypes three SNP, rs7308076 *CIT*, rs11787532 *ZFHX4*, and rs2248202 *IFNAR2* with only the KASP method due to the lack of specific restriction sites. Primer sequences used for RFLP were designed based on the GenBank reference sequence for each gene, as follows: Forward, 5′-TCACACATTGGTATGATTATTTGATTC-3′ and reverse, 5′-TTTGATCCTACTTGAATGTAACTGC-3′ for rs12557782 GRIA3 (NM_000828.4), restriction enzyme *Hea*III; forward, 5′-AAAGGCAGGGGGATGTCTAT-3′ and reverse, 5′-ATGATGGCTCGAAACTCACC-3′ for rs2229857 ADAR (NM_0,010,25107.2), restriction enzyme *Mbo*II; forward, 5′-AGTGACGCTGCCTCTTCTTC-3′ and reverse, 5′-CCCTGAGTACCCTTTGGTCA-3′ for rs733254 ZFAT (NM_02,0863.3), restriction enzyme *Xba*I; and: forward, 5′-GGTAGGAGGATTTCGAAGCA-3′ and reverse, 5′-GGTGGCTAAGGAAACCTTGA-3′ for rs9527281 STARD13 (NM_0,012,43476.2), restriction enzyme *Hyp*188III. The RFLP was conducted using the GoTaq Flexi DNA polymerase (Promega Corporation, Madison, WI, USA), in a DNA Engine Tetrad 2 (Bio-Rad Laboratories, Inc., Hercules, CA, USA) thermal cycler with conditions as follows: Initial denaturation at 95°C for 5 min; 34 cycles of 95°C for 1 min, 60.5°C for 45 sec, and 72°C for 1 min; followed by a final extension at 72°C for 7 min.

A total of seven SNPs were genotyped using KASP version 4.0 at Genoscreen (Lille, France). Briefly, KASP genotyping system allows SNPs to be detected via fluorescence resonance energy transfer (FRET). For each SNP, one common reverse primer and two allele-specific forward primers (that differ at their 3′ ends) were designed by Genoscreen. The DNA samples were transferred into 96-well plates and genotyped according to the KASP PCR protocol. Genotyping reactions were performed in HC16 thermal cyclers (LGC, Ltd., Teddington, UK) in a final volume of 5 *µ*l containing 2.5 *µ*l genomic DNA (12 ng/*µ*l), 2.5 *µ*l of 2X KASP reaction mix (containing Taq polymerase enzyme and ROX passive reference dye; KBioscience; LGC, Ltd.) and 0.07 *µ*l of the KASP assay primer mix (KBioscience; LGC, Ltd.). The following cycling conditions were used: A hot-start Taq polymerase activation step at 94°C for 15 min; followed by 10 touchdown cycles of 94°C for 20 sec, 65--57°C for 1 min (decreasing 0.8°C/cycle); and 26 cycles of 94°C for 20 sec and 57°C for 1 min. Fluorescence detection of the reactions was performed using a FRET reading instrument, and PHERAstar plate reader (BMG Labtech GmbH, Ortenberg, Germany) and genotyping data was analyzed with KlusterCaller software (Kbioscience; LGC, Ltd.).

Statistical analysis
--------------------

Statistical analysis was conducted using SPSS 19 (IBM SPSS, Armonk, NY, USA). Independent samples t-test and χ^2^ test were applied to compare the basic demographic data between case and control groups. The Hardy-Weinberg exact equilibrium test and the analysis of SNP association with MS (based on logistic regression) were performed using the web-tool SNPStats ([bioinfo.iconcologia.net/SNPstats](http://bioinfo.iconcologia.net/SNPstats), provided by the Catalan Institute of Oncology, Spain) ([@b27-mmr-14-04-3543]) and two-way contingency table analysis ([statpages.org/ctab2x2.html](http://statpages.org/ctab2x2.html)). The SHEsis software platform (<http://analysis.bio-x.cn/SHEsisMain.htm>) was also used for the association study ([@b28-mmr-14-04-3543],[@b29-mmr-14-04-3543]). CaTS software (<http://csg.sph.umich.edu/abecasis/CaTS/>) performed power calculations for the genetic association study. The Akaike Information Criterion (AIC) selected the genetic model illustrating the association of SNPs with MS. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

A total of 268 unrelated individuals with 112 controls, 64 female and 48 male) and 156 MS cases (88 female and 68 male) were observed in the present study. [Table I](#tI-mmr-14-04-3543){ref-type="table"} provides a summary of the demographic and clinical features of the study participants. No notable differences were detected between the MS and control groups.

[Table II](#tII-mmr-14-04-3543){ref-type="table"} presents the 7 SNPs described by Comabella *et al* ([@b14-mmr-14-04-3543]) as significantly associated with INF-β therapy in Spanish MS patients. The mean SNPs call rate was 98% in patients and controls. All the tested SNPs followed the Hardy--Weinberg equilibrium, with the exception of rs12557782 in the *GRIA3* gene. Thus, this polymorphism was discarded from further analyses.

[Tables III](#tIII-mmr-14-04-3543){ref-type="table"} and [IV](#tIV-mmr-14-04-3543){ref-type="table"} indicate the association of each SNP with MS risk in the 156 patients (for all patients, and women and men separately). Of the six SNPs, *ZFAT* rs733254 SNPs exhibited an allelic association with MS and P\<0.01 ([Table III](#tIII-mmr-14-04-3543){ref-type="table"}). The T allele frequency is significantly higher in the control group compared with the MS patients group \[odds ratio (OR)=0.53 and 95% confidence interval (CI), 0.37--0.77); P= 0.0004). However, a notable over-representation of the G allele \[OR=1.87 (95% CI, 1.30--2.70); P=0.0004\] was observed among MS cases ([Table III](#tIII-mmr-14-04-3543){ref-type="table"}). The aforementioned associations are more significant in women than in the total group \[P=0.0004, OR=0.420 (95% CI, 0.25--0.69); P=0.0002, OR=2.38 (95% CI, 1.45--3.91), respectively; [Table III](#tIII-mmr-14-04-3543){ref-type="table"}\].

Following application of the highly conservative Bonferroni correction for multiple tests, the two allelic associations remained significantly associated with MS susceptibility ([Table III](#tIII-mmr-14-04-3543){ref-type="table"}). At α=0.05, with the sample size used in the present study, the power for the significant association was 92%. These associations were not observed in men ([Table III](#tIII-mmr-14-04-3543){ref-type="table"}). The same was observed for TT and GG genotype frequencies of *ZFAT* rs733254 ([Table IV](#tIV-mmr-14-04-3543){ref-type="table"}). In female MS patients, the variant GG was significantly associated with increased risk of MS \[OR=2.17 (95% CI, 1.03--4.6); P=0.025\]. Subsequent to Bonferroni correction for multiple testing, the statistical significance was lost \[OR=2.17 (95% CI, 1.03--4.6); P=0.154\]. However, the genotype TT of *ZFAT* rs733254 was significantly associated with a decreased risk of MS \[OR=0.28 (95% CI, 0.12--0.64), P=0.00073\], and remained statistically significant following Bonferroni correction \[OR=0.28 (95% CI, 0.12--0.64); P=0.0044\]. At the same time, these associations were not observed in men.

None of the selected SNPs in *ADAR*, *STARD13*, *ZFHX4*, *CIT* and *IFNRA2* genes demonstrated any significant association with MS risk, even when analyzing gender separately ([Tables III](#tIII-mmr-14-04-3543){ref-type="table"} and [IV](#tIV-mmr-14-04-3543){ref-type="table"}).

Another model of association analysis was performed by logistic regression test. Consistent with the AIC, the *ZFAT* rs733254 was observed to be associated with MS by a recessive model ([Table V](#tV-mmr-14-04-3543){ref-type="table"}). As demonstrated by the OR, the variant TT was associated with reduced susceptibility to MS (OR=0.30 (95% CI, 0.17--0.55); P= 0.0001\].

The findings of the present study indicate that *ZFAT* rs733254 may be critical to MS development in women, however, this requires validation in studies with a larger sample size. However, in the male cohort it exhibited no significant association with MS.

Discussion
==========

GWAS are conducted in a defined ethnic setting in order to identify genes involved in the onset of numerous diseases. Nevertheless, validation of these data by independent studies in different ethnic groups remains an important area of research. Recent successes using GWAS approaches have identified seven gene variants that contribute to the IFN-β therapy response in Spanish MS patients ([@b14-mmr-14-04-3543]). However, none of these genes were previously confirmed as a MS risk gene. To investigate these findings in a different ethnic setting and determine population variability in the genome of MS patients, a genetic study of the reported seven SNPs in the Arabian Gulf population was conducted.

The present case-control study determined that rs733254 T\>G in intron 3 of the *ZFAT* gene was significantly associated with a risk of MS. To the best of our knowledge, no previous studies have demonstrated such an association. The rs733254 T allele was a statistically significant protective factor against MS \[OR=0.53 (95% CI, 0.37--0.77); P=0.0025\]. Furthermore, it was observed that the recessive model is the most fitting genetic model for *ZFAT* rs733254 ([Table V](#tV-mmr-14-04-3543){ref-type="table"}). As indicated by the OR, the variant TT was associated with reduced susceptibility to MS \[OR=0.30 (95% CI, 0.17--0.55); P=0.0001\]. Furthermore, the G allele was significantly associated with increased risk of MS \[OR=1.87 (95% CI, 1.30--2.70); P=0.0025\].

The observed risk with the G allele of *ZFAT* SNP is the same as in the previous Comabella *et al* (2009) GWAS study ([@b14-mmr-14-04-3543]) indicating that *ZFAT* rs733254 G allele may be critical to MS development and is a contributing factor to INF-β therapy response in MS patients. However, the sample size of INF-β non-responder MS patients (68 patients were recorded as responders, 17 as non-responders to IFN-β treatment) in the present study was not sufficiently large to replicate the GWAS data mentioned above. In the present study, the GG genotype of *ZFAT* SNP was identified as the risk genotype in the female group with frequencies of 0.460 in patients and 0.281 in controls. In the Spanish population, GG + GT genotypes were reported as risk genotypes associated with INF-β therapy response in MS.

No significant associations of rs7308076 *CIT*, rs2229857 *ADAR*, rs9527281 *STARD13*, rs11787532 *ZFHX4*, or rs2248202 *IFNAR2* with MS in the Arabian Gulf population were observed in the present study. Associations of certain SNPs are more consistent among populations than other SNPs. This may depend on allelic frequencies, localization in genes and chromosomes, different linkage disequilibrium patterns in populations, and the different evolutionary history of genes that affect complex diseases ([@b30-mmr-14-04-3543]).

The present study demonstrates, to the best of our knowledge, for the first time, that rs733254 T\>G variants in *ZFAT* gene confers risk for MS in the Arabian Gulf population in a gender-specific manner. *ZFAT* was highly associated with MS in women, but less so when the analysis was performed in men and women. ZFAT rs733254 may be key in MS development in women and could be validated in studies with a larger sample size. It was hypothesized that the gender-specific effects of a particular loci on MS susceptibility may result from gender-dependent differences in immune response ([@b31-mmr-14-04-3543]). Until recently, genes of the immune system have been observed to be associated with MS in a gender-specific way. SNPs in chemokine (C-X-C motif) ligand 16 ([@b32-mmr-14-04-3543]), brain-derived neurotrophic factor ([@b33-mmr-14-04-3543]) and HLA-DRB1\*1501 ([@b34-mmr-14-04-3543]) are associated with MS exclusively or with high significance in women.

The ZFAT gene was initially identified as a candidate gene for autoimmune thyroid disease via linkage and association analyses using 515 Japanese patients and 526 controls ([@b35-mmr-14-04-3543],[@b36-mmr-14-04-3543]). The ZFAT gene encodes a 1243-amino acid residue protein, including one AT-hook and 18 C2H2 zinc finger domains ([@b37-mmr-14-04-3543]). The mouse ZFAT protein is expressed in B and T lymphocytes. ZFAT is a critical transcription factor regulating the genes involved in immune responses ([@b37-mmr-14-04-3543]). Furthermore, the ZFAT protein is a key regulator involved in apoptosis and cell survival for immune-associated cells ([@b38-mmr-14-04-3543]).

Genetic analyzes conducted in the last decade have demonstrated a novel profile of MS pathogenesis and indicated a high degree of variability between individuals and populations. To establish efficient treatments for MS based on the pathogenesis and prognosis of individuals and to pave the way for novel MS therapies tailored to patients\' genetic background, further studies are required in different ethnic settings. Future large-scale GWAS (including other populations worldwide) and the meta-analysis of these studies may describe the complete profile of MS.

In conclusion, the present study provides supporting evidence for gender differences in the association of the *ZFAT* gene (rs733254 T\>G) with the pathogenesis of MS in the Arabian Gulf population. The current study suggests a genetic basis may account for the reported gender differences in MS risk, which demonstrates that genetic polymorphisms within immune-associated genes may have different effects in women and men. This suggests a novel research area in the genetics of the immune system response to autoimmune stimuli.

The authors wish to acknowledge Dr. Isa Alsharoqi (Department of Clinical Neurosciences, Salmaniya Medical Complex, Manama, Bahrain) and Dr. Farzana Al Sayed (Gulf Diabetes Specialist Center, Manama, Bahrain) for facilitating access to patients. The present study was supported by a research grant from the Arabian Gulf University (grant no. BIO01).

###### 

Demographic and clinical characteristics of subjects included in the present study.

  Parameter                     Control (n=112)   MS patients (n=156)   P-value
  ----------------------------- ----------------- --------------------- ---------
  Gender                                                                
   Female                       64 (42.1%)        88 (57.9%)            0.905
   Male                         48 (41.4%)        68 (58.6%)            0.905
  Age, years                                                            
   Female                       29.59±1.086       33.63±1.021           0.392
   Male                         28.46±1.266       33.56±1.006)          0.188
  Age at disease onset, years                                           
   Female                                         27.33±0.892           0.607
   Male                                           26.03±0.995           0.607
  EDSS score                                                            
   Female                                         2.7±0.179             
   Male                                           2.9±0.256             

Results are presented as the mean ± standard deviation. MS, multiple sclerosis; EDSS, expanded disability status scale.

###### 

Summary of selected single nucleotide polymorphisms.

  dbSNP ID     Gene      Location   Position
  ------------ --------- ---------- -----------------
  rs733254     ZFAT      8          Intron 3
  rs12557782   GRIA3     X          Intron 2
  rs2229857    ADAR      1          Exon 2/missense
  rs9527281    STARD13   13         Intron 1
  rs11787532   ZFHX4     8          Intron 3
  rs7308076    CIT       12         Intron 9
  rs2248202    IFNAR2    21         Intron 1

ZFAT, zinc finger and AT hook domain containing; GRIA3, glutamate receptor, ionotropic, AMPA 3; ADAR, adenosine deaminase, RNA-specific; STARD13, StAR-related lipid transfer (START) domain containing 13; ZFHX4, zinc finger homeobox 4; CIT, citron Rho-interacting serine/threonine kinase; IFNAR2, interferon (α, β and ω) receptor 2.

###### 

Allelic variants of selected SNPs in MS patients and healthy controls.

  SNP          Allele   AF      OR (95% CI), p/p^a^   AF                                     OR (95% CI), p/p^a^   AF      OR (95% CI), p/p^a^                                      
  ------------ -------- ------- --------------------- -------------------------------------- --------------------- ------- ---------------------------------------- ------- ------- --------------------------
  rs733254     T        0.365   0.518                 **0.53 (0.37--0.77), 0.0004/0.0025**   0.351                 0.562   **0.420 (0.25--0.69), 0.0002/0.0014**    0.382   0.457   0.73 (0.41--1.3), 0.276
  ZFAT         G        0.635   0.482                 **1.87 (1.30--2.70), 0.0004/0.0025**   0.649                 0.438     **2.38 (1.45--3.91), 0.0002/0.0014**   0.618   0.543   1.35 (0.79--2.32), 0.276
  rs2229857    A        0.314   0.330                 0.93 (0.63--1.36), 0.708               0.341                 0.344     0.98 (0.59--1.64), 1                   0.279   0.312   0.85 (0.46--1.57), 0.661
  ADAR         G        0.686   0.670                 1.08 (0.73--1.58), 0.708               0.659                 0.656     1.01 (0.61--1.68), 1                   0.721   0.688   1.17 (0.63--2.16), 0.661
  rs9527281    T        0.577   0.593                 0.94 (0.65--1.35), 0.788               0.653                 0.597     1.27 (0.77--2.10), 0.333               0.478   0.587   0.64 (0.36--1.14), 0.137
  STARD13      G        0.423   0.407                 1.07 (0.74--1.54), 0.788               0.347                 0.403     0.78 (0.47--1.29), 0.333               0.522   0.413   1.55 (0.90--2.74), 0.137
  rs11787532   C        0.266   0.248                 1.10 (0.73--1.67), 0.688               0.282                 0.281     1,00 (0.58--1.71), 1                   0.246   0.202   1.29 (0.65--2.56), 0.522
  ZFHX4        G        0.734   0.752                 0.90 (0.60--1.37), 0.688               0.718                 0.719     0.99 (0.58--1.71), 1                   0.754   0.798   0.77 (0.39--1.53), 0.522
  rs7308076    T        0.386   0.432                  083 (0.57--1.19), 0.323               0.414                 0.476     0.77 (0.47--1.26), 0.291               0.351   0.372   0.91 (0.51--1.63), 0.780
  CIT          C        0.614   0.568                   1.2 (0.39--1.74), 0.323              0.586                 0.524     1.29 (0.79--2.09), 0.291               0.649   0.628   1.09 (0.61--1.97), 0.780
  rs2248202    A        0.805   0.782                 1.11 (0.71--1.75), 0.514               0.826                 0.815     1.07 (0.57--2.05), 0.878               0.779   0.740   1.24 (0.65--2.40), 0.532
  IFNAR2       C        0.195   0.218                 0.87 (0.55--1.35), 0.514               0.174                 0.185     0.93 (0.49--1.76), 0.878               0.221   0.260   0.80 (0.42--1.55), 0.532

Bold indicates P\<0.05. MS, multiple sclerosis; SNP, single nucleotide polymorphism; AF, allele frequency; Cont., control; OR, odds ratio; CI, confidence interval at 95%; p, P-value calculated by χ^2^ test (df=1) for difference between cases and controls; p^a^, P-value following Bonferroni correction; ZFAT, zinc finger and AT hook domain containing; ADAR, adenosine deaminase, RNA-specific; STARD13, StAR-related lipid transfer (START) domain containing 13; ZFHX4, zinc finger homeobox 4; CIT, citron Rho-interacting serine/threonine kinase; IFNAR2, interferon (α, β and ω) receptor 2.

###### 

Association between selected SNP genotypes and MS risk.

  SNP          Genotype   GF           GF           GF                                                                                                                                    
  ------------ ---------- ------------ ------------ ---------------------------------------- ------------ ------------ ---------------------------------------- ------------ ------------ ---------------------------
  rs733254     TT         0.168 (26)   0.373 (41)   **0.34 (0.18--0.62), 0.00015/0.00093**   0.161 (14)   0.406 (26)   **0.28 (0.12--0.64), 0.00073/0.0044**    0.176 (12)   0.326 (15)   0.44 (0.17--1.15), 0.076
               GT         0.394 (61)   0.291 (32)   1.58 (0.90--2.76), 0.091                 0.379 (33)   0.312 (20)   1.34 (0.64--2.82), 0.490                 0.412 (28)   0.261 (12)   1.98 (0.81--4.88), 0.113
  ZFAT         GG         0.439 (68)   0.336 (37)   1.54 (0.90--2.64), 0.099                 0.460 (40)   0.281 (18)   **2.17 (1.03--4.6), 0.025/0.154 (NS)**   0.412 (28)   0.413 (19)   0.99 (0.43--2.28), 1
  rs2229857    AA         0.083 (13)   0.125 (14)   0.64 (0.26--1.51), 0.306                 0.091 (8)    0.141 (9)    0.61 (0.12--1.86), 0.436                 0.074 (5)    0.104 (5)    0.84 (0.20--3.58), 1
               GA         0.462 (72)   0.411 (46)   1.23 (0.73--2.07), 0.455                 0.500 (44)   0.406 (26)   1.46 (0.72--2.95), 0.323                 0.412 (28)   0.417 (20)   0.98 (0.43--2.22), 1
  ADAR         GG         0.455 (71)   0.465 (52)   0.96 (0.57--1.61), 0.902                 0.409 (36)   0.453 (29)   0.84 (0.41--1.68), 0.621                 0.515 (35)   0.479 (23)   1.15 (0.51--2.58), 0.851
  rs9527281    TT         0.353 (55)   0.380 (41)   0.89 (0.52--1.53), 0.697                 0.432 (38)   0.387 (24)   1.20 (0.59--2.46), 0.617                 0.250 (17)   0.370 (17)   0.57 (0.23--1.38), 0.212
               GT         0.449 (70)   0.426 (46)   1.09 (0.65--1.85), 0.801                 0.443 (39)   0.419 (26)   1.10 (0.54--2.24), 0.867                 0.456 (31)   0.435 (20)   1.09 (0.48--2.48), 0.850
  STARD13      GG         0.199 (31)   0.194 (21)   1.03 (0.53--1.99), 1                     0.125 (11)   0.194 (12)   0.59 (0.22--1.58), 0.261                 0.294 (20)   0.196 (9)    1.71 (0.64--4.63), 0.278
  rs11787532   CC         0.084 (13)   0.054 (6)    1.61 (0.54--4.94), 0.470                 0.080 (7)    0.062 (4)    1.31 (0.32--5.63), 0.760                 0.090 (6)    0.043 (2)    2.21 (0.38--16.70), 0.467
               GC         0.364 (56)   0.387 (43)   0.90 (0.53--1.54), 0.701                 0.402 (35)   0.438 (28)   0.86 (0.42--1.75), 0.739                 0.313 (21)   0.319 (15)   0.97 (0.40--2.34), 1
  ZFHX4        GG         0.552 (85)   0.559 (62)   0.97 (0.58--1.64), 1                     0.517 (45)   0.500 (32)   1.07 (0.55--2.15), 0.870                 0.597 (40)   0.638 (30)   0.84 (0.36--1.94), 0.699
  rs7308076    TT         0.149 (23)   0.200 (22)   0.70 (0.35--1.40), 0.320                 0.149 (13)   0.270 (17)   0.47 (0.19--1.14), 0.097                 0.149 (10)   0.106 (5)    1.47 (0.42--5.40), 0.583
               CT         0.474 (73)   0.464 (51)   1.04 (0.62--1.75), 0.901                 0.529 (46)   0.413 (26)   1.59 (0.79--3.24), 0.187                 0.403 (27)   0.532 (25)   0.59 (0.26--1.34), 0.187
  CIT          CC         0.377 (58)   0.336 (37)   1.19 (0.69--2.05), 0.518                 0.322 (28)   0.317 (20)   1.02 (0.48--2.17), 1                     0.448 (30)   0.362 (17)   1.43 (0.62--3.30), 0.440
  rs2248202    AA         0.636 (98)   0.600 (66)   1.16 (0.68--1.99), 0.607                 0.651 (56)   0.645 (40)   1.02 (0.49--2.15), 1                     0.618 (42)   0.542 (26)   0.00 (0.00--12.59), 0.448
               CA         0.338 (52)   0.364 (40)   0.94 (0.55--1.61), 0.857                 0.349 (30)   0.339 (21)   1.04 (0.49--2.20), 1                     0.324 (22)   0.396 (19)   0.73 (0.31--1.69), 0.438
  IFNAR2       CC         0.026 (4)    0.036 (4)    0.70 (0.14--3.44), 0.723                 0.000 (0)    0.016 (1)    0.00 (0.00--12.59), 0.419                0.059 (4)    0.062 (3)    0.94 (0.16--5.62), 1

MS, multiple sclerosis; SNP, single nucleotide polymorphism; GF, genotype frequency in MS patients vs. healthy controls; Cont., control; n, number of genotype carriers; OR, odds ratio; CI, confidence interval at 95%; p, P-value calculated by χ^2^ test (df=1) for difference between cases and controls;

p, P-value following Bonferroni correction; NS, not significant; ZFAT, zinc finger and AT hook domain containing; ADAR, adenosine deaminase, RNA-specific; STARD13, StAR-related lipid transfer (START) domain containing 13; ZFHX4, zinc finger homeobox 4; CIT, citron Rho-interacting serine/threonine kinase; IFNAR2, interferon (α, β and ω) receptor 2.

###### 

Association between rs733254 *ZFAT* and multiple sclerosis risk based on logistic regression test.

  SNP        Model                      OR (95% CI)             P-value      AIC
  ---------- -------------------------- ----------------------- ------------ -----------
  rs733254   C (GT vs. GG)              0.98 (0.53--1.80)       0.0003       336.5
             C (TT vs. GG)              0.30 (0.15--0.58)       0.0003       
             D \[(GT+TT) vs. GG\]       0.59 (0.35--1.01)       0.052        346.7
             **R \[TT vs. (GG+GT)\]**   **0.30 (0.17--0.55)**   **0.0001**   **334.5**
  ZFAT       L-A                        0.57 (0.41--0.79)       0.0006       338.8

SNP, single nucleotide polymorphism; ZFAT, zinc finger and AT hook domain containing; C, codominant model; D, dominant model; R, recessive model; L-A, Log-additive model; OR, odds ratio; CI, confidence interval at 95%; AIC, akaike information citerion. The best model is indicated in bold (the lowest AIC value).
